LLY

972.66

-2.04%↓

JNJ

222.08

-0.94%↓

ABBV

202.41

-1.46%↓

UNH

368.41

+0.16%↑

AZN

182.35

-1.44%↓

LLY

972.66

-2.04%↓

JNJ

222.08

-0.94%↓

ABBV

202.41

-1.46%↓

UNH

368.41

+0.16%↑

AZN

182.35

-1.44%↓

LLY

972.66

-2.04%↓

JNJ

222.08

-0.94%↓

ABBV

202.41

-1.46%↓

UNH

368.41

+0.16%↑

AZN

182.35

-1.44%↓

LLY

972.66

-2.04%↓

JNJ

222.08

-0.94%↓

ABBV

202.41

-1.46%↓

UNH

368.41

+0.16%↑

AZN

182.35

-1.44%↓

LLY

972.66

-2.04%↓

JNJ

222.08

-0.94%↓

ABBV

202.41

-1.46%↓

UNH

368.41

+0.16%↑

AZN

182.35

-1.44%↓

Strona główna・Stock List・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Open

SectorHealthcare

1.66

Buy Sell

Overview

Share price change

24h

Current

Min

1.65

Max

1.75

Key metrics
By Trading Economics
Income	-2.4M -40M
Sales	6.2M 45M
Profit margin	-90.427
Employees	485
EBITDA	-6M -38M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+31.58% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	-74M 481M
Previous open	1.66
Previous close	1.66

News Sentiment

By Acuity

50%

187 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

1.13 / N/A Support & Resistance

Pacific Biosciences of California Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 maj 2026, 23:41 UTC

Earnings

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 maj 2026, 21:40 UTC

Earnings

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 maj 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 maj 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 maj 2026, 23:13 UTC

Earnings

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 maj 2026, 23:13 UTC

Earnings

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 maj 2026, 23:12 UTC

Earnings

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 maj 2026, 23:11 UTC

Earnings

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 maj 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 maj 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 maj 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 maj 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 maj 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 maj 2026, 23:07 UTC

Earnings

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 maj 2026, 23:06 UTC

Earnings

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 maj 2026, 23:06 UTC

Earnings

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 maj 2026, 23:05 UTC

Earnings

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 maj 2026, 23:04 UTC

Earnings

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 maj 2026, 22:50 UTC

Earnings

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 maj 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 maj 2026, 22:11 UTC

Earnings

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 maj 2026, 22:11 UTC

Earnings

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 maj 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 maj 2026, 21:58 UTC

Earnings

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 maj 2026, 21:47 UTC

Market Talk

Earnings

Costco Posts 13% Sales Growth in April -- Market Talk

6 maj 2026, 21:46 UTC

Earnings

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 maj 2026, 21:40 UTC

Earnings

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 maj 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 maj 2026, 21:32 UTC

Hot Stocks

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 maj 2026, 21:29 UTC

Earnings

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

31.58% upside

12 Months Forecast

Average 2.25 USD 31.58%

High 3 USD

Low 1 USD

Based on 5 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Pacific Biosciences of California Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.13 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

187 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.